Intra Cellular Therapies reported $75.46M in Selling and Administration Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US $ 96.68M 9.23M
Aptinyx Inc APTX:US $ 5.78M 661K
Biocryst Pharmaceuticals BCRX:US $ 34.28M 1.1M
Biogen BIIB:US $ 634.9M 153M
Bristol Myers Squibb BMY:US $ 1.83B 523M
Cytokinetics CYTK:US $ 33.07M 736K
Esperion Therapeutics ESPR:US $ 30.38M 5.29M
Gilead Sciences GILD:US $ 1.08B 567M
Halozyme Therapeutics HALO:US $ 13.83M 60K
Intra Cellular Therapies ITCI:US $ 75.46M 4.22M
JAZZ PHA JAZZ:US 308.81M 53.95M
Johnson & Johnson JNJ:US $ 5.94B 1.22B
Marinus Pharmaceuticals MRNS:US 11.74M 1.12M
Minerva Neurosciences NERV:US $ 3.03M 398.63K
Nektar Therapeutics NKTR:US $ 27.34M 4.8M
Novartis NVS:US 3.5B 486M
Prothena PRTA:US 11.84M 371K
Redhill Biopharma RDHL:US 20.38M 2.81M
Supernus Pharmaceuticals SUPN:US $ 90.46M 11.02M
United Therapeutics UTHR:US $ 79M 47.9M
Vanda Pharmaceuticals VNDA:US $ 40.85M 7.4M